Clinician-focused platform reaches 96% accuracy on the United States Medical Licensing Examination (USMLE), outperforming industry peers on standardized tests
Pathway announced that its proprietary large-language model (LLM) scored 96% on a validated set of United States Medical Licensing Examination (USMLE) questions, the highest accuracy yet reported for a specialized medical AI. The result strengthens Pathway’s position as a leading evidence-based decision-support tool for frontline clinicians.
Health Technology Insights: Altesa BioSciences announces Katharine Knobil, M.D. as Chief Medical Officer
Pathway “Deep” achieves 96 % accuracy on the USMLE, the highest publicly reported score for any medical AI model.
In head-to-head testing, Pathway’s “Deep” AI model surpassed domain-specific peers MediSearch Pro, OpenEvidence and Hippocratic AI, and outperformed generalist systems such as ChatGPT 4o, o1, and GPT-4.5 on complex diagnostic scenarios. Independent academic validation studies are currently underway to further corroborate these groundbreaking results.
Health Technology Insights: AI Mapping Tech Unfold Outperforms MRI in Prostate Cancer
Pathway attributes the performance to its transparent just-in-time reasoning pipeline, which combines retrieval-augmented generation (RAG) with chain-of-thought (CoT) analysis and agentic tool calling. The architecture allows the model to evaluate multiple information sources simultaneously, surface potential knowledge gaps, generate follow-up questions, and apply clinical scoring and prediction rules—all without adding latency for the user.
“Trust and transparency are foundational for bringing AI into clinical workflows,” said Dr. Louis Mullie, Chief Medical Officer at Pathway. “Clinicians need speed and accuracy, but they also need verifiable evidence. Pathway’s assistant reveals its reasoning step-by-step and links every recommendation to expert-vetted guidelines and a comprehensive drug reference. By giving users the context to double-check dosages and key guidance, Pathway helps them leverage AI efficiently while maintaining full control over patient-safety decisions.”
This milestone builds on Pathway’s rapid growth and industry recognition. In 2024 Pathway became the first generative-AI medical tool to receive continuing-medical-education (CME) co-accreditation, making every clinical question asked through the platform eligible for CME credit. Earlier this year the company added HIPAA support for Pathway Plus subscribers, enabling secure, compliant integration of patient-specific data into AI queries. Pathway also recently surpassed one million registered users across more than 10,000 healthcare institutions, underscoring its widespread adoption and trust within the medical community.
Health Technology Insights: Foundation Fighting Blindness and Alma Address Mental Health Gap
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
